AU2007212345A1 - Compounds and compositions as protein kinase inhibitors - Google Patents

Compounds and compositions as protein kinase inhibitors Download PDF

Info

Publication number
AU2007212345A1
AU2007212345A1 AU2007212345A AU2007212345A AU2007212345A1 AU 2007212345 A1 AU2007212345 A1 AU 2007212345A1 AU 2007212345 A AU2007212345 A AU 2007212345A AU 2007212345 A AU2007212345 A AU 2007212345A AU 2007212345 A1 AU2007212345 A1 AU 2007212345A1
Authority
AU
Australia
Prior art keywords
methyl
ylamino
pyrimidin
phenyl
trifluoromethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2007212345A
Other languages
English (en)
Inventor
Pamela A. Albaugh
Qiang Ding
Nathanael S. Gray
Pingda Ren
Taebo Sim
Xia Wang
Qiong Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IRM LLC
Original Assignee
IRM LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IRM LLC filed Critical IRM LLC
Publication of AU2007212345A1 publication Critical patent/AU2007212345A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2007212345A 2006-02-06 2007-02-06 Compounds and compositions as protein kinase inhibitors Abandoned AU2007212345A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US77104506P 2006-02-06 2006-02-06
US60/771,045 2006-02-06
PCT/US2007/003319 WO2007092531A2 (en) 2006-02-06 2007-02-06 Compounds and compositions as protein kinase inhibitors

Publications (1)

Publication Number Publication Date
AU2007212345A1 true AU2007212345A1 (en) 2007-08-16

Family

ID=38255301

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007212345A Abandoned AU2007212345A1 (en) 2006-02-06 2007-02-06 Compounds and compositions as protein kinase inhibitors

Country Status (10)

Country Link
US (1) US20090069327A1 (https=)
EP (1) EP1981870A2 (https=)
JP (1) JP2009525978A (https=)
KR (1) KR20080092412A (https=)
CN (1) CN101421262A (https=)
AU (1) AU2007212345A1 (https=)
BR (1) BRPI0707666A2 (https=)
CA (1) CA2637225A1 (https=)
RU (1) RU2008135690A (https=)
WO (1) WO2007092531A2 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200811134A (en) 2006-07-12 2008-03-01 Irm Llc Compounds and compositions as protein kinase inhibitors
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
PT2300013T (pt) 2008-05-21 2017-10-31 Ariad Pharma Inc Derivados de fósforo como inibidores de cinases
EP2307456B1 (en) 2008-06-27 2014-10-15 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
UY32582A (es) * 2009-04-28 2010-11-30 Amgen Inc Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
AU2011289661C1 (en) * 2010-08-07 2014-12-04 The Research Foundation For The State University Of New York Oral compositions comprising a zinc compound and an anti-microbial agent
PL2647637T3 (pl) * 2010-12-02 2016-06-30 Medpacto Inc Pochodna purynylopirydynyloamino-2,4-dlfluorofenylo-sulfonamidu, jej farmaceutycznie dopuszczalna sól, sposób jej wytwarzania oraz zawierająca ją jako składnik aktywny kompozycja farmaceutyczna o aktywności hamującej kinazę Raf
US9834518B2 (en) 2011-05-04 2017-12-05 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in EGFR-driven cancers
KR20180084153A (ko) * 2011-06-10 2018-07-24 메르크 파텐트 게엠베하 Btk 억제 활성을 갖는 피리미딘 및 피리딘 화합물의 조성물 및 제조방법
US9061028B2 (en) * 2012-02-15 2015-06-23 Natco Pharma Limited Process for the preparation of Nilotinib
US20150166591A1 (en) 2012-05-05 2015-06-18 Ariad Pharmaceuticals, Inc. Methods and compositions for raf kinase mediated diseases
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
CA3015417A1 (en) 2016-03-01 2017-09-08 Propellon Therapeutics Inc. Inhibitors of wdr5 protein-protein binding
JP7624690B2 (ja) 2016-03-01 2025-01-31 プロペロン セラピューティクス インコーポレイテッド Ｗｄｒ５タンパク質－タンパク質結合の阻害剤
EP3848370B1 (en) * 2016-10-14 2025-05-07 Takeda Pharmaceutical Company Limited Tyk2 inhibitors and uses thereof
WO2020056132A1 (en) * 2018-09-13 2020-03-19 University Of Southern California Novel fgfr inhibitors and uses thereof
KR102878873B1 (ko) * 2019-02-14 2025-10-31 브리진 바이오사이언시스, 인코포레이티드 암 치료를 위한 fgfr 억제제
AU2021358123A1 (en) 2020-10-05 2023-06-08 Enliven Inc. 5- and 6-azaindole compounds for inhibition of bcr-abl tyrosine kinases
CN117222640A (zh) * 2021-04-03 2023-12-12 先声再明医药有限公司 作为fgfr抑制剂的杂环化合物及其应用
WO2024159094A1 (en) * 2023-01-27 2024-08-02 Enliven Inc. Pyrimidinyl (hetero)aromatic aminopyridine compounds for inhibition of raf kinases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004278413B2 (en) * 2003-09-30 2008-07-31 Irm Llc Compounds and compositions as protein kinase inhibitors
EP1751136B1 (en) * 2004-05-07 2014-07-02 Amgen Inc. Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer

Also Published As

Publication number Publication date
WO2007092531A3 (en) 2007-10-18
JP2009525978A (ja) 2009-07-16
US20090069327A1 (en) 2009-03-12
WO2007092531A2 (en) 2007-08-16
CA2637225A1 (en) 2007-08-16
EP1981870A2 (en) 2008-10-22
KR20080092412A (ko) 2008-10-15
BRPI0707666A2 (pt) 2011-05-10
RU2008135690A (ru) 2010-03-20
CN101421262A (zh) 2009-04-29

Similar Documents

Publication Publication Date Title
AU2007212345A1 (en) Compounds and compositions as protein kinase inhibitors
AU2007305016B2 (en) Compounds and compositions as protein kinase inhibitors
AU2007317349B2 (en) Compounds and compositions as protein kinase inhibitors
AU2006247757B2 (en) Compounds and compositions as protein kinase inhibitors
AU2005254982B2 (en) Compounds and compositions as protein kinase inhibitors
US7589101B2 (en) Compounds and compositions as protein kinase inhibitors
US8426404B2 (en) Pyrimidine-substituted benzimidazole derivatives as protein kinase inhibitors
US20090181991A1 (en) Compounds and compositions as protein kinase inhibitors
US8592433B2 (en) Compounds and compositions as protein kinase inhibitors
MX2008009925A (en) Compounds and compositions as protein kinase inhibitors

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted